關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Biotechnology」新聞搜尋結果, 共 1913 篇 ,以下為 1 - 24 篇 訂閱此列表,掌握最新動態
Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

BEIJING and PARIS, June 7, 2024 /PRNewswire/ -- Tsingke successfully wrapped up its debut at TIDES USA 2024, the premier event for oligonucleotides, peptides, mRNA, and genome editing. Held from May 14-17 at the Hynes Convention Center in Boston, the conference brought together over 150 leading scientists and more than 150 exhibitors, fostering vibrant exchanges and cutting-edge research. At booth 832, Tsingke showcased its advanced biotechnological solutions featuring a comprehensive synthetic industrial chain. Key highlights included high-quality oligo synthesis, peptide synthesis, synthesis equipment, synthetic reagents, consumables, tailored to meet the needs of both research and preclinical. (Tsingke at TIDES USA 2024) Engagement and Feedback: During the four-day event, Tsingke engaged with numerous experts and companies, discussing advancements in oligo synthesis and related fields. Many attendees expressed high praise for Tsingke's innovative solutions and the practical benefits they offer. Additionally, many participants showed interest and intention to collaborate on Tsingke's oligo synthesizer and raw materials. Innovation and Future Prospects: Tsingke highlighted its recent breakthroughs, such as advanced oligo modification techniques and rapid gene synthesis processes. Tsingke's infrastructure, including a 12,000-square-meter R&D site and a 100,000-grade clean production workshop, supports its efficient and high-quality DNA/RNA synthesis services. Industry Impact: Tsingke's dedication to innovation and quality is reflected in its portfolio of over 300 intellectual property rights, earning the trust of more than 200,000 customers worldwide. By driving innovations in oligo synthesis, peptide, and gene technologies, Tsingke contributes significantly to clinical therapeutics and drug development, enhancing human health and well-being. Market and Industry Trends The TIDES USA 2024 conference highlighted the growing demand for advanced biotechnological solutions, focusing on expediting R&D and improving CMC efficiency. Tsingke's offerings are well-aligned with these industry trends, positioning the company for continued growth and impact. About Tsingke Beijing Tsingke Biotech Co., Ltd. is a global leader in DNA/RNA synthesis, driven by the mission of advancing "Biotech for a better world." Committed to innovation, Tsingke provides comprehensive services to researchers and enterprises worldwide, fostering progress in biotechnology.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 670 加入收藏 :
Körber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking

LONDON, May 8, 2024 /PRNewswire/ -- The new Competitive Assessment by global technology intelligence firm ABI Research provides an in-depth and unbiased examination of the solutions offered by 13 manufacturing execution system (MES) software suppliers targeting pharmaceutical, biotech, and cell & gene manufacturing. The companies evaluated and ranked are: Market Leaders: Körber Pharma, Siemens, Apprentice,  Rockwell Automation, and TulipMainstream: Dassault Systèmes, GE Digital, Honeywell, Emerson, MPDV, MasterControl, ParsecFollowers: Sepasoft "Overall, the MES software market for pharmaceutical, biotechnology, and cell & gene manufacturing is highly competitive, and the top innovators offer very comparable solutions. Technology vendors are aggressively developing new functionality, and competitors must closely watch and identify areas where they can match or leapfrog software capabilities," explains James Prestwood, Industrial & Manufacturing Industry Analyst at ABI Research. A total of ten overarching criteria were chosen for the purposes of this analysis and segmented across innovation and implementation clusters. These include how comprehensive the solution is and what innovative functionality it offers, data visibility, accessibility, and security within the platform, the user experience, and the capacity of worker augmentation, the MES's contribution to manufacturers digital thread capabilities, and the alignment of the MES software with the pharmaceutical, biotechnology, and cell & gene manufacturing markets. In addition, the report evaluates MES vendor's ability to deliver rapid time to value, their experience in delivering the software to manufacturers, the extensiveness of the vendor's partnership base, the support for SME manufacturers, and the comprehensiveness of the software's pricing options. Körber Pharma and Siemens came out on top in the competitor ranking, with both firms scoring well across all criteria. Apprentice ranked as the top innovator in the assessment, offering a wide range of strong functionality designed specifically for life sciences manufacturing, an excellent cloud-native design, and comprehensive low/no-code capabilities.  Dassault Systèmes scored particularly well in the implementation criteria, ranking second, with its center-of-excellence deployment model allowing manufacturers to quickly and consistently deploy and scale DELMIA Apriso. "Pharmaceutical, biotech, and cell & gene manufacturing have been slow to embrace digital transformation but are now catching up. The industry's strict regulations mean new solutions must be proven, and a premium should be placed on extensive deployment experiences when choosing solutions and technology partners," Prestwood concludes. These findings are from ABI Research's MES Software for Pharmaceutical, Biotech, and Cell & Gene Therapy Manufacturing Competitive Ranking report. This report is part of the company's Industrial and Manufacturing Markets research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Competitive Ranking reports offer comprehensive analysis of implementation and innovation strategies to offer unparalleled insight into a company's performance and standing compared to its competitors. About ABI Research ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers. ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。 For more information about ABI Research's services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com. Contact Info: GlobalDeborah Petrara Tel: +1.516.624.2558 pr@abiresearch.com 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 139 加入收藏 :
HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications

JAVENÉ, France, May 6, 2024 /PRNewswire/ -- HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisition includes Modern Meadow's platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3). With this platform, within a world-class scientific research center, the company also integrates a team recognized for its cutting-edge expertise in the field. HTL Biotechnology makes a notable entry into recombinant human collagen for cosmetic and medical uses, addressing not only identified Vegan ethical commitments needs but also unique and differentiating properties. The rhCOL3, developed in the United States and produced in Europe, has already raised the interest of numerous players in the cosmetic and aesthetic industry. In a nascent market with high demand set to surpass the billion-dollar mark soon, this recombinant human collagen holds significant promise. HTL Biotechnology's ambition, through this acquisition, is to drive innovation in the company's historical segments, including aesthetic medicine, rheumatology, and ophthalmology, as well as explore new therapeutic areas. The synergy between HTL Biotechnology's high-quality GMP biofermentation expertise and this new platform of recombinant proteins will enable the development of disruptive innovations, leveraging a combination of biopolymers and accelerating the company's innovative capabilities. HTL Biotechnology will now offer a broad and distinctive range of products through its platform, including pharmaceutical-grade hyaluronic acid, polynucleotides, and products in development such as heparosan or botulinum toxin as a neuromodulator. Additionally, with this acquisition, HTL Biotechnology gains a platform for human recombinant collagens. The company is also strengthening its presence on the North American continent with, on one hand, the teams from HTL Biotechnology Manufacturing Inc. (HTL BMI) based in the state of Massachusetts, and on the other hand, the arrival of this new organization based in Nutley (NJ). François Fournier, CEO of HTL Biotechnology, states: "I am thrilled with the commercialization of this new Vegan biopolymer, the diversification of our activity, and the prospects that this acquisition gives us to innovate even further, together. HTL Biotechnology thus becomes a pioneer in the market for human recombinant collagen, where the company was a pioneer 30 years ago in the bioproduction of hyaluronic acid. The depth of our biopolymer portfolio is unique, and it is with great pride that we will be able to serve our clients even better.  I am delighted to welcome, on behalf of HTL Biotechnology, the beauty and biomedical teams from Modern Meadow." "This strategic acquisition marks an acceleration in the development of HTL Biotechnology, its international expansion, and the diversification of its portfolio. It reinforces its leadership position in biopolymers by offering a broad and innovative range" comments Paul Navarre, Chairman of HTL Biotechnology. About HTL HTL Biotechnology is a French biotech and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers. These biopolymers are used by healthcare companies for the development of treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. For over 30 years, HTL Biotechnology has been a driving force behind innovation in the sector, collaborating with research entities and biotech companies to meet tomorrow's medical needs (regenerative medicine, drug delivery, etc.). HTL Biotechnology is a fast-growing international company, exporting nearly 80% of its production to more than 30 countries. To meet these growing global needs for biopolymers, HTL Biotechnology has also opened subsidiaries in Singapore and the United States, with the construction of a neuromodulator production unit (HTL BMI – Massachusetts). Historically based in Javené (Brittany), the company brings together production, innovation, research and development, as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. To learn more about HTL Biotechnology: https://htlbiotech.com/  LinkedIn: HTL Biotechnology Press contact Nathalie Chevallon – nchevallon@htlbiotech.com – 07 61 45 26 85Olivier Clement – oclement@apcoworldwide.com – 07 64 47 24 07Agence APCO : Nina Pereira – npereira@apcoworldwide.com – 06 80 20 23 02  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 410 加入收藏 :
Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support

HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the management of Hong Kong-based and Singapore-based startups seeking private equity investments from international funds. Witnessing the initial success of numerous ambitious Hong Kong startups, Valtech is committed to supporting them throughout their expansion journey. Our company has meticulously crafted a workflow and refined the presentation of valuations for startups to better align with the expectations of investors and founders. The consulting work at Valtech aims to strike a balance, offering the best service for independent price discovery when a startup plans a fundraising campaign or an investor seeks an unbiased evaluation of the founders' asking price. Valtech's approach to startup valuation involves conducting comprehensive research to identify and gather data on comparable deals relevant to the target. This research typically encompasses no fewer than hundreds of potentially relevant private deals and publicly traded companies with valuation metrics pertinent to the target. Max Tsang, Director of Valtech, highlighted, "Companies in the biotechnology industry can be in the pre-clinical phase or different phases of clinical trials with a probability of success or failure. A standard valuation report focuses on discussions of assumptions and three major methodologies: the cost approach, market approach, and income approach. While suitable for financial reporting or independent statutory reporting, a standard valuation report may not suffice. Supplementary materials such as tables, charts, and graphical presentations can enhance the presentation and comprehension of the valuation for a typical startup." As of today, Valtech professionals have contributed to multiple startup projects from HKSTP and Cyberport in Hong Kong, some of which have successfully completed Series A and later funding rounds. We take pride in being trusted valuation advisors who have worked with many fast-growing business stories in Hong Kong. In 2023, Valtech's directors were invited by HKSTP and INNOHK's representatives to deliver a talk to some of their startup members on valuation. Alongside basic concepts and key factors in valuation, Jimmy Wong, another Director of Valtech, shared advanced techniques such as roadmap on valuation, milestone-based market approach, and simulation-based valuations. Valtech has also received commendation from an international pharmaceutical company for its remarkable dedication and delivery of profound valuation insights. Initially founded and based in Hong Kong, Valtech expanded into Singapore in 2023. With a well-designed consulting workflow, proprietary applications, and an ISO 9001 certified quality management system, our consulting team can now serve clients not only in Hong Kong but also in Mainland China, Singapore, and Southeast Asia. Valtech has successfully completed valuation projects for Middle East-based companies and US-listed firms. Valtech's qualified team comprises members with PhDs, CPA (HKICPA), CFA, Chartered Valuation Surveyors of the Royal Institution of Chartered Surveyors, and valuers accredited with Business Valuation (ABV) by AICPA and CVA qualifications in Singapore. Valtech continues to expand into more markets by leveraging its valuation platform and recruiting local experts.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 415 加入收藏 :
Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support

HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the management of Hong Kong-based and Singapore-based startups seeking private equity investments from international funds. Witnessing the initial success of numerous ambitious Hong Kong startups, Valtech is committed to supporting them throughout their expansion journey. Our company has meticulously crafted a workflow and refined the presentation of valuations for startups to better align with the expectations of investors and founders. The consulting work at Valtech aims to strike a balance, offering the best service for independent price discovery when a startup plans a fundraising campaign or an investor seeks an unbiased evaluation of the founders' asking price. Valtech's approach to startup valuation involves conducting comprehensive research to identify and gather data on comparable deals relevant to the target. This research typically encompasses no fewer than hundreds of potentially relevant private deals and publicly traded companies with valuation metrics pertinent to the target. Max Tsang, Director of Valtech, highlighted, "Companies in the biotechnology industry can be in the pre-clinical phase or different phases of clinical trials with a probability of success or failure. A standard valuation report focuses on discussions of assumptions and three major methodologies: the cost approach, market approach, and income approach. While suitable for financial reporting or independent statutory reporting, a standard valuation report may not suffice. Supplementary materials such as tables, charts, and graphical presentations can enhance the presentation and comprehension of the valuation for a typical startup." As of today, Valtech professionals have contributed to multiple startup projects from HKSTP and Cyberport in Hong Kong, some of which have successfully completed Series A and later funding rounds. We take pride in being trusted valuation advisors who have worked with many fast-growing business stories in Hong Kong. In 2023, Valtech's directors were invited by HKSTP and INNOHK's representatives to deliver a talk to some of their startup members on valuation. Alongside basic concepts and key factors in valuation, Jimmy Wong, another Director of Valtech, shared advanced techniques such as roadmap on valuation, milestone-based market approach, and simulation-based valuations. Valtech has also received commendation from an international pharmaceutical company for its remarkable dedication and delivery of profound valuation insights. Initially founded and based in Hong Kong, Valtech expanded into Singapore in 2023. With a well-designed consulting workflow, proprietary applications, and an ISO 9001 certified quality management system, our consulting team can now serve clients not only in Hong Kong but also in Mainland China, Singapore, and Southeast Asia. Valtech has successfully completed valuation projects for Middle East-based companies and US-listed firms. Valtech's qualified team comprises members with PhDs, CPA (HKICPA), CFA, Chartered Valuation Surveyors of the Royal Institution of Chartered Surveyors, and valuers accredited with Business Valuation (ABV) by AICPA and CVA qualifications in Singapore. Valtech continues to expand into more markets by leveraging its valuation platform and recruiting local experts.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 349 加入收藏 :
L'Oréal-UNESCO For Women in Science 2023 Supports Three Promising Researchers from Singapore in the fields of Material Engineering, Biotechnology, and Sustainable Chemistry

Three promising women researchers emerged as winners out of 42 applicants this year Each winner will receive an endowment worth S$10,000 to advance their research The L'Oréal-UNESCO For Women in Science aims to help bridge the gender gap for women scientists SINGAPORE, Nov. 28, 2023 /PRNewswire/ -- L'Oréal Singapore celebrated three outstanding women researchers in the L'Oréal-UNESCO For Women in Science 2023 program. In an awards ceremony held in Kuala Lumpur on Wednesday, 22nd November 2023, Dr. Leow Wan Ru, Dr. Yang Le, and Dr. Xue Shifeng emerged as the three deserving beneficiaries, each receiving S$10,000 to advance their research. The beneficiaries of the L’Oréal-UNESCO For Women in Science 2022 program (L to R) -Dr. Shifeng Xue, Dr. Leow Wan Ru, Mr Tomas Hruska, Managing Director of L’Oréal Singapore and Dr. Le Yang at the awards ceremony in Kuala Lumpur last week. (Photo credit: L’Oréal Singapore) Dr. Leow is currently a scientist at the Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), researching the use of renewable energy to power chemical reactions. Dr. Yang focuses on the research of PROFESS or Printed Organic Flexible Electronics and Sensors. Her decision to delve into the field of organic and flexible electronics was driven by a deep-seated conviction for innovation and a desire to contribute to a more sustainable and user-centric future. Meanwhile, Dr. Xue's research is centered on the study of epigenetic repression in development and disease, focusing on human congenital disorders. In layman terms, she studies how genes turn on and off, in embryonic development and in disease. Tomas Hruska, Managing Director of L'Oréal Singapore, said "With science as one of our foundational pillars, L'Oréal is dedicated to fostering the potential of girls and women in STEM fields. Our commitment is evident through the L'Oréal-UNESCO For Women in Science program, where we recognize and celebrate outstanding women researchers to help bridge gender gaps. By doing so, we aim to encourage women to pursue their aspirations in science because the world needs science, and science needs women." The L'Oréal-UNESCO Fellowship for Women in Science provides an endowment to help women scientists advance their research – which is in line with the L'Oréal Fondation's three-pronged mission of promoting the progress of inclusive beauty, scientific research, and climate change sustainability. This year marks the 25th global anniversary of the esteemed program. A global initiative by the Fondation L'Oréal, the program was launched in Singapore back in 2009. It has to-date assisted 27 women scientists locally and disbursed over S$270,000 worth of endowment. L'Oréal Singapore partnered with Agency for Science, Technology and Research (A*Star) for this year's program where the esteemed Professor Andy Hor, the Deputy Chief Executive (Research), served as the President Jury. The beneficiaries were selected after stringent assessments by a panel of juries comprising of established researchers such as Professor Andy Hor; Professor Liu Bin, Deputy President (Research and Technology) from National University of Singapore; Professor Lam Yeng Ming, Chair of School of Materials Science and Engineering from Nanyang Technological University Singapore; Professor Archan Misra, Vice Provost (Research) from Singapore Management University; Dr Wan Yue, Deputy Executive Director of Genome Institute of Singapore from A*STAR; Professor Yang Hui Ying from Singapore University of Technology and Design (SUTD); and Associate Professor Low Hong Yee, Head of Pillar, Engineering Product Development (EPD) from SUTD. For more information, please visit - https://www.forwomeninscience.com/.  About L'Oréal Singapore L'Oréal Singapore was established in 1990 and currently has around 20 international brands across luxury, masstige, consumer and hair categories. With more than 900 employees and a Research & Innovation Centre, L'Oréal Singapore is consistently voted as one of the top employers, and was ranked in Universum 2017 as the #1 FMCG Company to Work For. Since 2009, the For Women In Science program is one key program that recognizes talented young women pursuing research in Singapore, while Brandstorm has been leading the field as an innovation incubator for talents and projects since 2001. L'Oréal Singapore is also committed to sustainability, ethics and the community, with multiple initiatives that meet environmental, social and consumer needs. Find out more at https://www.loreal.com/en/singapore/  About L'Oréal Fondation The L'Oréal Fondation embodies the L'Oréal Group's commitment to embracing corporate citizenship through acts of generosity. It focuses on science and beauty – the two pillars on which L'Oréal has built its success for over a century – as the strategic focus for the Foundation's actions. Science stands at the very heart of the Fondation's activities. Its star initiative, the "For Women in Science'' programme developed in partnership with UNESCO, recognizes women who have contributed to scientific progress on every continent, and promotes scientific advances worldwide. The Fondation's other commitments focus on the belief that beauty should be accessible to everyone and that it plays a key role in moving our society forward – through transforming lives through reconstructive surgery, socio-aesthetic workshops or education – as a means of improving the life quality of vulnerable people, helping them return to normal life, and restoring the self-esteem and dignity they need to make their way in society. About UNESCO Since its creation in 1945, UNESCO has pursued its mission of promoting science at the service of sustainable development and peace. It focuses on policy development and building capacities in science, technology and innovation and promoting and strengthening science education and engineering. UNESCO fosters the sustainable management of freshwater, oceans and terrestrial resources, the protection of biodiversity, and using the power of science to cope with climate change and natural hazards. The Organization also works to eliminate all forms of discrimination and to promote equality between men and women, especially in scientific research.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 753 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈